Relatively protected from the development PubMed ID:http://www.ncbi.nlm.nih.gov/pubmed/27107493 of tumors. In a clinical setting, however, antiangiogenic drugs would be preferably used in combination with chemotherapeutic?2013 Chammas and Cell Adhesion and Cancer Group; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Chammas and Cell Adhesion and Cancer Group BMC Proceedings 2013, 7(Suppl 2):K16 http://www.biomedcentral.com/1753-6561/7/S2/KPage 2 ofdrugs. Vasculature function, however is also critical for the proper delivery of chemotherapeutic drugs to tumors, specific therapeutic windows for the application of antiangiogenic drugs need to be identified. This notion will be further discussed. Altogether, the examples above call for a necessary understanding of tumor physiology, which seems to be under appreciated in the design of experimental/ clinical trials.Competing interests There are no competing interests in this presentation. Acknowledgments FAPESP (Center for Cell-based Therapy Research), Instituto Nacional de Ci cia e Tecnologia- Redoxoma and UICC-Yamagiwa Yoshida Grant. Published: 4 Aprildoi:10.1186/1753-6561-7-S2-K16 Cite this article as: Chammas and Cell Adhesion and Cancer Group: Tumors as complex organs: are cancers manageable through the modification of their microenvironment? BMC Proceedings 2013 7(Suppl 2):K16.Submit your next manuscript to BioMed Central and take full advantage of:?Convenient online submission ?Thorough peer review ?No space constraints or color figure charges ?Immediate publication on acceptance ?Inclusion in PubMed, CAS, Scopus and Google Scholar ?Research which is purchase PM01183 freely available for redistributionSubmit your manuscript at www.biomedcentral.com/submit
Al-Allaf et al. International Archives of Medicine 2010, 3:36 http://www.intarchmed.com/content/3/1/REVIEWOpen AccessLDLR-Gene therapy for familial hypercholesterolaemia: problems, progress, and perspectivesFaisal A Al-Allaf1,2*, Charles Coutelle2, Simon N Waddington2,3,4, Anna L David4, Richard Harbottle2, Michael Themis2,Abstract Coronary artery diseases (CAD) inflict a heavy economical and social burden on most populations and contribute significantly to their morbidity and mortality rates. Low-density lipoprotein receptor (LDLR) associated familial hypercholesterolemia (FH) is the most frequent Mendelian disorder and PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/27864321 is a major risk factor for the development of CAD. To date there is no cure for FH. The primary goal of clinical management is to control hypercholesterolaemia in order to decrease the risk of atherosclerosis and to prevent CAD. Permanent phenotypic correction with single administration of a gene therapeutic vector is a goal still needing to be achieved. The first ex vivo clinical trial of gene therapy in FH was conducted nearly 18 years ago. Patients who had inherited LDLR gene mutations were subjected to an aggressive surgical intervention involving partial hepatectomy to obtain the patient’s own hepatocytes for ex vivo gene transfer with a replication deficient LDLR-retroviral vector. After successful re-infusion of transduced cells through a catheter placed in the inferior mesenteric vein at the time of liver resection, only low-level expression of the transferred LDLR gene was observed in the five patients enrolled in the trial. In co.